Specialty retailer of kids’ merchandise, The Children’s Place (PLCE), saw its stock slipping 3.26% on Thursday during pre-market trading. The company posted weaker-than-expected earnings for the first quarter of 2018, negatively impacted by winter storms and unseasonably cold temperatures that persisted across the major markets.
The Secaucus, NJ-based firm saw its earnings fall to $31.5 million or $1.78 a share from $36.2 million or $1.97 a share a year ago. Excluding items, earnings fell to $1.87 a share from $1.95 a share. Sales fell marginally by 0.1% to $436.3 million, and comparable retail sales slipped 1.8% in the first quarter of 2018.
Recently, the company signed an exclusive licensing agreement with a Chinese specialty kids’ apparel retailer Zhejiang Semir Garment. This deal enables Children’s Place to expand into Greater China. This partnership is expected to generate sales between $125-150 million by 2022.
The company’s successful turnaround is due to the CEO Jane Elfers. Under her leadership, the company began closing the oversized stores as well the ones with overpriced leases. And by 2020, the company plans to close some 300 stores. During the first quarter, the company closed 12 stores and did open any new store. Children’s Place ended the first quarter with 1,002 stores, and under the fleet optimization initiative that was introduced in 2013, the Company has closed 181 stores.
For Fiscal 2018, the retailer is expecting adjusted earnings to be in the range of $7.95-$8.20 a share. Total net sales is expected to be in the range of $1.920-$1.935 billion, and a comparable retail sales rise of about 3.5- 4.5%. For the upcoming second quarter, EPS is expected to be in the range of $0.51-0.61.
“The strong sales momentum has continued, and quarter to date, we are currently running a positive 24% comp. We expect that this pent-up demand for seasonal product will continue and enable us to deliver strong second quarter results,” said Elfers.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on